Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
about
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesSelective use of sorafenib in the treatment of thyroid cancerInternal radiation therapy: a neglected aspect of nuclear medicine in the molecular eraThe Evolving Treatment Landscape for Metastatic Differentiated Thyroid CancerThe treatment landscape in thyroid cancer: a focus on cabozantinibContemporary approaches for imaging skeletal metastasisMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsProgress in molecular-based management of differentiated thyroid cancerSpinal metastasis in thyroid cancerMetastatic mechanisms in follicular cell-derived thyroid cancerChemotherapy and chemoprevention by thiazolidinedionesCurrent status and future perspectives in differentiated thyroid cancerVemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialLenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerThe Treatment of Well-Differentiated Thyroid CarcinomaIdentification of a recurrent STRN/ALK fusion in thyroid carcinomas2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerDetermination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer.GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupNonanaplastic follicular cell-derived thyroid carcinoma: mitosis and necrosis in long-term follow-up.Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Improved detection of lung or bone metastases with an I-131 whole body scan on the 7th day after high-dose I-131 therapy in patients with thyroid cancerTiming of multikinase inhibitor initiation in differentiated thyroid cancer.Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.Differentiated Thyroid Cancer-Treatment: State of the Art.Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy.Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.Thoracic metastasectomy for thyroid malignanciesXB130, a novel adaptor protein, promotes thyroid tumor growth.Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I.Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer.BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients
P2860
Q24596266-6A070364-40FE-4D6B-9E34-2B37B1EBB81EQ26751274-B675C1D1-EB39-4390-AF1A-9D6CBFB846ECQ26752891-CD436ABE-0C55-4B00-91E1-6F44E5823A0CQ26786554-13115461-78B7-44B4-82C5-863846EFB7F3Q26795503-7168F2DE-34E7-421F-9123-ADB229A45434Q26796404-01798026-6C30-4B0A-93E6-5A3C747BE6EEQ26798170-1C6C60B3-38E2-4D78-AC11-56D0E26557BAQ26821959-49D96BD7-968E-46ED-8364-16323B6223C4Q26862841-4FC814AD-5A49-4556-8133-4C8C5405EC8FQ26863326-6233D9AD-6B5A-4B50-A8B9-A2C54E12A8E7Q26999887-DFFD300C-C77F-4D03-A333-806BF8FE9E48Q27003934-BF6A5F67-62BC-472B-9AED-14333A39BADAQ27005646-A661FB4E-B46D-499B-BD12-63F7D4C3ED0DQ27011352-F41C8C38-B324-4B14-8E09-AC29E935E07FQ27024484-5B13F8D0-B68D-4D26-A9E1-F29FB9F76458Q27853396-CD99FB7C-7F35-4918-9682-3311C16153BCQ28072655-F1D25E0D-0CED-492F-A658-F41A7BF5FA29Q28084401-E52C7C16-5856-469A-BBCB-C8BFD8F00F6EQ28539208-DA491D51-25D5-4EE8-9761-008F4975973FQ30367068-61CC90C3-C18E-4774-99B4-AF1A7619FAAAQ31114848-8F287D43-3CA0-4897-9465-30CB8C7BCF22Q33397349-79395458-D809-4D62-8B20-3FDD223C0633Q33425571-725472FC-9AF9-46EB-9C04-A67A14332285Q33587905-32607885-B109-44ED-B236-4CA940789E27Q33644361-25B55440-6485-44B2-B430-86BEFE4B6CC3Q33672603-57067D66-1D2A-4410-A4EF-97E8ED6EA875Q33682381-BD71B375-2FF0-451D-B6E9-71AD881AF111Q33704024-923832BE-6325-451B-AB99-D543C22FF578Q33733408-23E9AD4F-90C6-4E7A-9D11-58EB412AE432Q33736109-BE89D0AC-F1B3-4BAD-A37A-561CF8203C79Q33839037-E565D078-5397-4F9E-813F-106615958E7EQ33871894-690D42F5-06A6-44E7-A041-67E497E399B1Q33927272-4C43E152-7F5E-41D2-A360-4BCD1F3E0620Q33973831-B8466BF3-4141-4740-AEC9-9F1B5406FC49Q34018753-8FFD0EC3-1B70-4CFE-9342-A8EFADEEF0E1Q34094842-DC3A9BD6-EE94-4256-86B5-F1BAA0A622F3Q34158435-D59FBD3F-2B43-4F16-9E8D-58E26AF571ACQ34206340-0AAE1782-EB6C-4DF1-9EF4-4A24A0A8AF98Q34453011-6B00A03C-D543-43C3-9EBE-D0CE265D034BQ34637861-4576D1FB-0FE7-4DF9-ABE2-5E5A258CBBF3
P2860
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@ast
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@en
type
label
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@ast
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@en
prefLabel
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@ast
Long-term outcome of 444 patie ...... limits of radioiodine therapy.
@en
P2093
P356
P1476
Long-term outcome of 444 patie ...... limits of radioiodine therapy
@en
P2093
De Vathaire F
Leboulleux S
Lumbroso JD
Schlumberger M
Travagli JP
P304
P356
10.1210/JC.2005-2838
P407
P577
2006-05-09T00:00:00Z